metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus Standard of Care (SoC)
	durvalumab alone vs. Standard of Care (SoC)	1	-852 [-2197; 493] /10000 48/62 vs. 55/64	292 [-648; 1233] /10000 58/62 vs. 58/64	-